TGF-β, the potent inducer of tumor progression and metastasis (87, 88), can augment CCL22 production by reducing the level of its upstream antagonist miR-34a in hepatocellular carcinoma (HCC) (89). This evidence concerns the gene CCL22 and hepatocellular carcinoma.